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Of the three mammalian CDK-activating Cdc25 protein phosphatases (Cdc25A, B, and 
C), Cdc25A protein is degraded via SCFβTrCP-mediated ubiquitylation following 
genomic insult; however, the regulation of the stability of the other two Cdc25 proteins 
is not well understood. Previously, we showed that Cdc25B is primarily degraded by 
cellular stresses that activate stress-activated MAP kinases, such as c-Jun NH2-terminal 
kinase (JNK) and p38. Here, we report that Cdc25B was ubiquitylated by SCFβTrCP E3 
ligase upon phosphorylation at two serine (Ser) residues in the βTrCP-binding 
motif-like sequence 94DAGLCMDSPSP104. Point mutation of these Ser residues to 
alanine (Ala) abolished the JNK-induced ubiquitylation by SCFβTrCP, and point mutation 
of DAG to AAG or DAA eradicated both βTrCP binding and ubiquitylation. Further 
analysis of the mode of βTrCP binding to this region revealed that the PEST-like 
sequence from 82ESS to 94DAG is critically involved in both the βTrCP binding and 
ubiquitylation of Cdc25B. Furthermore, the phospho-mimetic substitution of all 10 Ser 
residues from 82ESS to SPSP104 to Asp resulted in βTrCP binding. Collectively, these 
results indicate that stress-induced Cdc25B ubiquitylation by SCFβTrCP requires the 




Cdc25 dual-specificity phosphatases promote cell cycle progression via the 
activation of cyclin-dependent kinase (CDK) cyclin by removing inhibitory phosphate 
groups on CDK (Morgan, 1995; Boutros et al., 2006). Higher Metazoa possess three 
isoforms of Cdc25, i.e., Cdc25A, B, and C. These are largely considered to serve roles 
in different cell cycle phases: Cdc25A in the G1/S to S phase, and Cdc25B and C in the 
G2/M to M phase (Boutros et al., 2006). However, this is not strictly correct because the 
depletion of either one or two Cdc25 genes does not produce a defective phenotype in 
the normal cell cycle, indicating that their roles overlap in somatic cell cycle control 
(Chen et al., 2001; Lincoln et al., 2002; Ferguson et al., 2005; Ray et al., 2007; Lee et 
al., 2009). 
Of the three mammalian Cdc25 isoforms, Cdc25A has received special attention 
because it is a target of the DNA replication/damage checkpoint (Donzelli and Draetta, 
2003; Bartek et al., 2004) and is the only Cdc25 that is essential to mouse 
embryogenesis (Ray et al., 2007; Lee et al., 2009). Cdc25A is phosphorylated rapidly 
by CHK1 upon genomic damage/replication arrest, and this is followed by the 
phosphorylation of critical serine (Ser) residues in the βTrCP-binding DSG motif by 
NEK11 (Busino et al., 2003; Jin et al., 2003; Melixetian et al., 2009), which initiates 
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SCFβTrCP-mediated ubiquitylation and degradation (Busino et al., 2004). Moreover, 
Cdc25A is directly linked to tumorigenesis, and the frequent overexpression of Cdc25A 
in human cancers is well documented (Kristjansdottir and Rudolph, 2004; Boutros et al., 
2007). 
The WD repeat-containing F-box protein βTrCP is a substrate-binding 
component of SCF (Skp1/Cul1/F-box protein) E3 ubiquitin ligase that recognises the 
doubly phosphorylated conserved motif DSGxxS (S can be replaced by T, and x 
represents any amino acid; Winston et al., 1999; Latres et al., 1999). SCFβTrCP targets a 
number of proteins that regulate the cell cycle and apoptosis (Frescas and Pagano, 2008). 
In particular, some proteins that control the G2/M transition, such as Cdc25A, Emi1, 
Wee1A, and Bora, are SCFβTrCP substrates, and most of them contain the 
above-mentioned βTrCP-binding sequence (Busino et al., 2003; Jin et al., 2003; 
Margottin-Goguet et al., 2003; Guardavaccaro et al., 2003; Watanabe et al., 2004; Seki 
et al., 2008). Wee1 kinase is also a substrate of SCFβTrCP, but its proposed 
βTrCP-binding sequence deviates from the consensus sequence (Watanabe et al., 2004). 
The consensus sequence and its deviated phosphopeptides bind βTrCP by forming 
hydrogen bonds and electrostatic interactions (Wu et al., 2003). In addition to such 
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phosphopeptides, Cdc25A and Cdc25B possess the non-phosphorylated βTrCP-binding 
sequence DDGxxD (Kanemori et al., 2005). 
Similar to Cdc25A, Cdc25B can transform pRB-negative cells or normal cells 
when co-expressed with the oncogenic ras (Galaktionov et al., 1995). Cdc25B 
overexpression is also found in human cancers and is correlated with a poor prognosis, 
as in the case of Cdc25A (Kristjansdottir and Rudolph, 2004; Boutros et al., 2007). The 
tumorigenic activity of Cdc25B is partly explained by an increase in hyperplasia or 
susceptibility to carcinogens in Cdc25B transgenic mice (Ma et al., 1999; Yao et al., 
1999). Moreover, Cdc25B overexpression accelerates mitotic entry (Karlsson et al., 
1999) and overrides the radiation-induced G2 checkpoint in vitro (Miyata et al., 2001). 
Recently, we showed that Cdc25B is degraded rapidly by non-genotoxic stimuli 
that activate stress-responsive MAP kinases, such as c-Jun N-terminal kinase (JNK) and 
p38 (Uchida et al., 2009). Our results suggested that these kinases phosphorylate 
specific Ser residues in the N-terminal region (S101 and S103) to induce Cdc25B 
degradation. We also found that HeLa cells expressing the non-phosphorylatable S101A 
mutant Cdc25B were more refractory to anisomycin-induced G2 arrest than wild-type 
HeLa cells. 
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Here, we report that JNK-induced Cdc25B ubiquitylation is mediated by F-box 
protein βTrCP-containing SCF ubiquitin ligase. We show that S101 and S103 are 
phosphorylated upon non-genotoxic stress and that βTrCP binds the sequence around 
S101/103 of Cdc25B in a phosphorylation-dependent manner, even when the DSG 
consensus βTrCP binding sequence is replaced with DAG. Our data also indicate that 
full binding and ubiquitylation of Cdc25B by SCFβTrCP requires an upstream ESS-rich 
PEST-like sequence, as well as DAG and S101/S103 phosphorylation. 
 
Results 
Ubiquitylation of Cdc25B is carried out by SCFβTrCP and is controlled by JNK 
Our previous report suggested that non-genotoxic stress-induced Cdc25B degradation 
was mediated by the ubiquitin-proteasome pathway via S101 and S103 phosphorylation 
by JNK/p38 (Uchida et al., 2009). Fig. 1A shows that the amino acid sequence 
surrounding Cdc25B S101/103 is quite similar to that in Cdc25A, which is a substrate 
of SCFβTrCP E3 ubiquitin ligase (Busino et al., 2003; Jin et al., 2003). Despite the 
overall similarity, the critical βTrCP-binding motif of Cdc25A (DSG) is replaced with 
DAG in Cdc25B, and DAG is reported to be inactive for βTrCP binding in humans and 
Xenopus Cdc25A (Busino et al., 2003; Jin et al., 2003; Kanemori et al., 2005). 
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The corresponding region of Cdc25B, including the human splice variants 
Cdc25B2 and Cdc25B3 and mouse Cdc25B1, has a similar amino acid sequence (Fig. 
1A; Baldin et al., 1997; Kakizuka et al., 1992). As indicated in Fig. 1B, human 
Cdc25B3, mouse Cdc25B1, and human Cdc25B1 were also degraded on coexpression 
with JNK or p38 (hereafter, we refer to human Cdc25B1 as Cdc25B). Interestingly, the 
Cdc25B/D94A mutant was refractory to JNK- or p38-induced degradation, suggesting 
the involvement of βTrCP binding (Fig. 1B). 
Next, we investigated the JNK-dependent interaction between βTrCP1 and 
Cdc25B. We compared βTrCP binding to the Cdc25B of the wild type and a mutant that 
lacked the constitutive βTrCP-binding motif by mutating 254DDG to DAA, which 
hereafter is referred to as Cdc25BDAA. Although wild-type Cdc25B bound βTrCP1 
irrespective of the JNK activity, Cdc25BDAA interacted with βTrCP1 in a 
JNK-dependent manner (Fig. 1C). In wild-type Cdc25B, JNK induced Cdc25B 
degradation and apparent Cdc25B binding was not as enhanced. Given the JNK-induced 
Cdc25B degradation that occurred in wild-type Cdc25B, several times more βTrCP was 
estimated to bind Cdc25B on co-expression with JNK. Likewise, the Cdc25B 
N-terminal fragment displayed JNK-dependent βTrCP1 binding, whereas the C-terminal 
fragment with the DDG site showed that βTrCP bound in a JNK-independent manner 
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(Fig. 1D). Furthermore, Cdc25BDAA interacted with βTrCP1 and βTrCP2, but not with 
other F-box proteins, such as Skp2 and Cdc4 (Fig. 1E). Cdc25BDAA was stabilised when 
cotransfected with the F-box deletion mutant βTrCP1ΔF, which lacks ubiquitylation 
activity due to its inability to bind to the core SCF complex, but retains 
substrate-binding ability via an intact WD domain (Fig. 1E). 
Next, we investigated the ubiquitylation of Cdc25B by SCFβTrCP in vitro. 
35S-labelled Cdc25BDAA was efficiently ubiquitylated by SCF containing βTrCP1 or 
βTrCP2 in a JNK-dependent manner. In contrast, no ubiquitylated signal was detected 
when Skp2 or Cdc4 was used as the F-box protein (Fig. 2A). Furthermore, βTrCP1ΔF 
did not ubiquitylate Cdc25B (Fig. 2B). Note that SCFβTrCP1 and SCFβTrCP2 could 
ubiquitylate Cdc25BDAA without JNK, but JNK clearly enhanced the ubiquitylation (Fig. 
2A and 2B). A high level of ubiquitylation was observed in the absence of JNK when 
wild-type Cdc25B was used for the in vitro ubiquitylation assay (Fig. 2C). Nevertheless, 
slight enhancement of Cdc25B ubiquitylation by SCFβTrCP1 was observed in the 
presence of JNK activity (Fig. 2C). These results indicate that SCFβTrCP binds and 
ubiquitylates Cdc25B in a JNK-dependent manner, which is independent of the DDG 
constitutive binding site, and that a new JNK-regulated βTrCP-binding site is located in 
the N-terminal 175 amino acids of Cdc25B. 
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Our previous report suggested that S101 and S103 were possible target sites of 
JNK or p38 (Uchida et al., 2009). Therefore, we assessed the contributions of S101 and 
S103 to SCFβTrCP-mediated Cdc25BDAA ubiquitylation. As indicated in Fig. 2D, whereas 
the ubiquitylation of Cdc25B was greatly compromised by S101A or S103A mutations, 
it was almost completely abolished with a S101/103A double mutant. These results 
indicate that the effects of S101 and S103 on Cdc25B ubiquitylation were collaborative. 
Other Cdc25B proteins, such as human Cdc25B3 and mouse Cdc25B1, were also 
ubiquitylated by SCFβTrCP1 in the presence of JNK1 (Fig. S1A). Intriguingly, 
Cdc25BD94A was hardly ubiquitylated (Fig. S1A), suggesting that D94 in DAG is 
involved in JNK-induced Cdc25B ubiquitylation. Moreover, in such wild-type or 
mutant Cdc25B, βTrCP1binding to Cdc25B proteins were roughly proportional to their 
ubiquitylation level (Fig. S1B).  Collectively, these results clearly indicate that 
JNK-induced Cdc25B degradation is mediated by SCFβTrCP1, and that the 
phosphorylation of Cdc25B S101 and S103 plays an important role in this process. 
 
JNK-induced Cdc25B degradation is aborted by βTrCP depletion 
Next, we assessed the effects of βTrCP depletion on JNK-induced Cdc25B 
degradation using siRNA that targets both βTrCP1 and βTrCP2. We used either one 
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siRNA used in previous reports (Margottin-Goguet et al., 2003; Guardavaccaro et al., 
2003; denoted here as pan-βTrCP) or two in combination, which enabled us to 
knockdown either βTrCP1 or βTrCP2 specifically (denoted as βTrCP1 + 2). The effect 
of βTrCP depletion on introducing these siRNAs to HeLa-W40 cells that stably express 
FLAG-Cdc25B (Uchida et al., 2009) is shown in Fig. S2A (we show only the 
expression of βTrCP1, due to the lack of a specific antibody to βTrCP2). The results 
also indicated that the application of such siRNA to HeLa-W40 cells enhanced the 
expression of FLAG-Cdc25B and endogenous Cdc25A, suggesting that both Cdc25A 
and Cdc25B are destroyed via a βTrCP-mediated pathway, even in the absence of 
cellular stress (Fig. S2A). 
First, we examined the stability of endogenous Cdc25B after siRNA depletion of 
βTrCP1 and 2 with either siRNA for pan-βTrCP or combined siRNA for βTrCP1 and 2. 
As indicated in Fig. 3A, βTrCP depletion endowed dramatic resistance to endogenous 
Cdc25B under anisomycin stress. Moreover, transiently expressed Cdc25BDAA also 
became refractory to the JNK-induced degradation on βTrCP1/2 depletion (Fig. S2B). 
As the depletion of βTrCP1 and 2 with the two siRNA treatments gave similar results 
(Fig. 3A and S2A), we mainly used pan-βTrCP siRNA in the subsequent experiments. 
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Next, we asked whether the half-life of Cdc25B was affected by βTrCP 
depletion. HeLa-W40 cells stably expressing FLAG-Cdc25B were depleted of 
βTrCP1/2 with pan-βTrCP siRNA and the expression of Cdc25B protein was 
determined in the presence of cycloheximide. As indicated in Fig. 3B, wild-type 
Cdc25B appeared to be stabilised in βTrCP-depleted cells. Interestingly, the steady-state 
expression of constitutively expressed Cdc25BDAA in HeLa-DAA34 cells was also 
enhanced by βTrCP depletion (Fig. 3C), suggesting that the SCFβTrCP-mediated 
ubiquitin–proteasome pathway controls Cdc25B stability in unstressed conditions, 
through a site other than the DDG βTrCP-binding site. 
We further investigated the involvement of βTrCP in anisomycin-induced 
Cdc25B degradation. FLAG-Cdc25BWT-expressing HeLa-W40 cells were transfected 
with either luciferase or pan-βTrCP siRNA, followed by a 50 ng/mL anisomycin 
challenge. βTrCP1/2 depletion strongly compromised anisomycin-induced Cdc25B 
degradation (Fig. 3D). βTrCP depletion of FLAG-Cdc25BDAA-expressing HeLa-DAA34 
cells had similar effects (Fig. S2B). Collectively, these results unequivocally indicate 
that SCFβTrCP directly controls the non-genotoxic stress-induced instability of Cdc25B. 
Furthermore, these results also suggest that a site other than the constitutive binding site 
of DDG controls the steady-state stability of Cdc25B. 
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JNK phosphorylates Cdc25B under stressful conditions 
Next, we investigated whether JNK/p38 phosphorylated S101 and S103 by 
raising antibodies that recognised S101-, S103-, or S101/103-phosphorylated Cdc25B; 
the antibody specificity is shown in Fig. S3A. Using these antibodies, we investigated 
the phosphorylation status of S101 and S103 under either unstressed or stressed 
conditions. Conventional HeLa cells were not useful in these experiments because we 
could not recover enough Cdc25B by immunoprecipitation to detect Cdc25B 
phosphorylation. Then, we used HeLa-W40 cells were used for phosphorylation 
analyses. Although a slight, but obvious, phospho-S101 signal was detected under 
unstressed conditions, S101 phosphorylation increased dramatically within 5 min of the 
50 ng/mL anisomycin treatment, concomitant with p38 activation judging from the 
appearance of the phosphorylated form of MK2 (Fig. 4A). Unlike S101, the S103 
phosphorylation signal was undetectable at time 0. A slight increase in phosphorylation 
was detected at 5 min and a much stronger signal was detected at 10 min, at which point 
JNK was fully activated judging from the phospho-c-Jun signal. The results for 
phospho-S103 were similar to those for S101/103 double phosphorylation, in which the 
maximum level was detected at 10 min. Cdc25B phosphorylation decreased at 15 min 
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and disappeared completely thereafter due to Cdc25B degradation. Similar results were 
obtained for stress induced with 300 mM NaCl (Fig. 4B) or ultraviolet (UV) irradiation 
(Fig. S3B). The steady-state phosphorylation of S101 and the similarity in the pattern 
between phospho-S103 and phospho-S101/103 suggest that the phosphorylation of 
S103 occurs in S101-phosphorylated Cdc25B, because S101 is always phosphorylated 
in the absence of stress. 
Next, we investigated the effects of p38 inhibitors (i.e., SB202190 and 
PD169316; abbreviated SB and PD, respectively) or JNK inhibitors (i.e., SP600125 or 
SP) on Cdc25B phosphorylation in HeLa-W40 cells. First, we determined suitable 
concentrations of these inhibitors for the specific inhibition of the respective kinases,  
because these kinases are often cross-inhibited by such inhibitors. As shown in Fig. S4A, 
20 µM SB inhibited both p38 and JNK activity judging from the disappearance of the 
phospho-MK2 and phospho-c-Jun signals, respectively, and it specifically inhibited p38 
at a concentration as low as 5 µM without JNK inhibition. Figs. S4B and S4C also 
indicate that 5 µM PD and 20 µM SP are suitable for the specific inhibition of p38 and 
JNK, respectively, without obvious cross-inhibition. As indicated in Fig. 4C, 
anisomycin-induced S101 phosphorylation was reduced by the p38 inhibitors SB and 
PD, but these inhibitors did not affect S103 phosphorylation. In comparison, the JNK 
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inhibitor SP completely inhibited S103, and modest inhibition of S101 phosphorylation 
was also observed. The role of JNK in S103 and S101 phosphorylation was also 
indicated by the siRNA depletion of JNK1 and JNK2 in anisomycin-treated HeLa-W40 
cells, where the phospho-S101 signal was reduced and the phospho-S101/103 signal 
was almost completely abolished by the knockdown of both JNK1 and 2 (Fig. 4D). In a 
similar context, the clear reduction of the expression of endogenous Cdc25B by the 
transfection of wild-type, but not the kinase-dead mutant JNK1, also suggests that JNK 
functions in the degradation of endogenous Cdc25B (Fig. S4D). 
Collectively, these and our previous results indicate that the enhanced 
phosphorylation at S101 caused by p38 and JNK and de novo S103 phosphorylation by 
JNK play critical roles in stress-induced Cdc25B degradation. Furthermore, the 
phospho-S101 signal detected under unstressed conditions did not disappear completely 
with the p38 inhibitors or JNK inhibitor, suggesting that an unidentified kinase(s) that 
phosphorylates S101 is involved in steady-state Cdc25B degradation. 
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The βTrCP-binding motif-like DAG is essential for SCFβTrCP-mediated Cdc25B 
ubiquitylation 
The above results suggested that DAG, currently believed to be inactive, is 
functional in βTrCP-mediated Cdc25B ubiquitylation. To explore this possibility, we 
made a mutant Cdc25B in which DAG was mutated to AAG (D94A), as the D (Asp) in 
DSG plays a critical role in substrate binding to βTrCP (Wu et al., 2003), and 
investigated whether the DAG in Cdc25B functions in JNK-induced βTrCP binding. 
FLAG-Cdc25BD94A was cotransfected with βTrCP1 in the presence or absence of JNK1, 
and its binding to βTrCP1 was determined. Interestingly, Cdc25BD94A failed to bind 
βTrCP1 (Fig. 4A). Cdc25BG96A (DAA instead of DAG) was also unable to bind βTrCP1 
(Fig. 4A). Furthermore, Fig. S5A shows that both Cdc25BD94A and Cdc25BG96A were 
refractory to JNK-induced degradation (see also Fig. 1B). As expected, the Cdc25B 
S101/103A double mutant also lost βTrCP-binding ability. These results suggest that 
the Cdc25B peptide from 94DAG to 101SPSP is a minimal requirement for βTrCP 
binding (see Fig. 1A). Moreover, the steady-state expression of such mutant Cdc25B 
was much higher than that of the wild type (Fig. 5A). Therefore, the DAG sequence 
seems to be deeply involved in both the steady-state and stress-induced degradation of 
Cdc25B. 
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Next, we investigated how mutations in the DAG sequence affected in vitro 
Cdc25B ubiquitylation. Cdc25BD94A was not ubiquitylated by SCFβTrCP1, even in the 
presence of JNK activity; its ubiquitylation level was much less than that of the 
S101/103 double mutant (Fig. 5B). Cdc25B ubiquitylation was also greatly 
compromised by a G96A mutation, suggesting that G96 plays a role in Cdc25B binding 
to βTrCP. Cdc25BD94A was phosphorylated at S101/103 when JNK1 was cotransfected 
(Fig. S5B), showing that the phosphorylation of SPSP occurs irrespective of DAG. 
These results indicate that DAG in Cdc25B is necessary for ubiquitylation by SCFβTrCP. 
To elucidate whether a peptide encompassing DAG to SPSP was sufficient for 
βTrCP binding, we analysed βTrCP1 binding based on DAGLCMDSPSP peptides, 
including the unphosphorylated, phospho-S101, and phospho-S101/103 forms. 
Peptide-conjugated beads were incubated with crude cell extracts prepared from 
βTrCP1-transfected Cos7 cells, and peptide-bound βTrCP1 was detected by 
immunoblotting. The unphosphorylated and phosphorylated IκBα peptides containing 
the conserved consensus βTrCP-binding sequence were used as controls. Fig. 5C shows 
that βTrCP1 barely bound the Cdc25B phospho-peptide under conditions where strong 
binding to the phosphorylated IκBα peptide was detected. Faint βTrCP1 signals that 
indicated binding to the doubly phosphorylated Cdc25B peptide were in fact detected 
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by longer exposure. Taken together, these results strongly support the idea that DAG is 
a critical sequence for JNK-induced Cdc25B ubiquitylation, but that the doubly 
phosphorylated DAGLCMDSPSP alone is insufficient for βTrCP binding. 
 
The PEST-like sequence plays an important role in SCFβTrCP-mediated Cdc25B 
ubiquitylation 
Compared to Cdc25A, human Cdc25B possesses a longer PEST-like sequence 
that is rich in E (Glu) and S (Ser) but lacks P (Pro), and is located upstream from DAG 
(Fig. 1A). This PEST-like sequence may contribute to βTrCP binding because 
phosphorylation or the presence of acidic amino acids N-terminal to the consensus 
DSG/DDG sequences facilitates βTrCP binding (Jin et al., 2003; Kanemori et al., 2005; 
Westbrook et al., 2008). The PEST-like sequence in Cdc25B consists of 12 amino acids, 
which comprise three ESS units and one LSS unit. We mutated all eight Ser to 
non-phosphorylatable Ala to make S83/84/86/87/89/90/92/93A and examined its 
binding to βTrCP1. The Cdc25B8SA mutant (denoted “8SA (–PEST)” in Fig. 5) was 
unable to bind βTrCP1 and was resistant to JNK-induced degradation (Fig. 6A and 
S6A). 
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Next, we examined how many of the Cdc25B ESS/LSS sequences were 
necessary for βTrCP binding. We made a series of mutants with Ser-to-Ala mutations in 
the AA units, in which 2SA represents S83/84A, 4SA represents S83/84/86/87A, 6SA 
represents S86/87/89/90/92/93A, and 8SA is as described above (-PEST; see Fig. 6B) in 
the Cdc25DAA background. The βTrCP-binding activity of these mutants was roughly 
proportional to the number of intact SS sequences (Fig. 6B). Consistent with these 
results, the degree of JNK-dependent ubiquitylation decreased in Cdc25B that lacked 
SS sequences (Fig. 6C). Cdc25B with fewer SS sequences was more refractory to 
JNK-induced degradation (Fig. S6B). Of the four 2SA mutants (i.e., S83/84A, S86/87A, 
S89/90A, and S92/93A), the mutant with SS mutations closest to DAG (S92/93A) was 
the most refractory to JNK-induced degradation and the least ubiquitylated, suggesting 
that ESS phosphorylation closer to DAG is more important for degradation (S6C). The 
mutation in either E88 or E91 did not have any effect on JNK-induced degradation (Fig. 
S6D), excluding the possibility that the PEST-like sequence itself is a core 
βTrCP-binding site. Moreover, S101 and S103 is phosphorylated in Cdc25B8SA, 
indication the phosphorylation of S101 and S103 independent of the PEST-like 
sequence (Fig. S6E). Collectively, these results clearly indicate that a PEST-like 
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sequence located upstream of DAG plays a critical role in SCFβTrCP-mediated Cdc25B 
ubiquitylation. 
 
A stretch of PEST-like sequence up to 101SPSP of Cdc25B is a possible minimum 
sequence required for JNK-induced βTrCP binding 
Next, we investigated the requirement of the PEST-like sequence and 101SPSP in 
βTrCP binding. Given the difficulty synthesising Ser-rich peptides and their 
phosphorylated forms, we made GST-fused peptides running from 82ESS to 101SPSP 
and their phospho-mimetic mutants, purified them from E. coli, and investigated their 
binding to βTrCP1. The GST-fused peptides used were as follows: 10S 
(non-phosphorylated form), 8D2S (S-to-D mutation in the PEST-like sequence), 8S2D 
(101DPDP mutant), and 10D (all S to D) (Fig. 7A). Such E. coli-produced proteins were 
mixed with Myc-βTrCP1-expressing Cos7 cell extracts in the presence of 1 µM 
staurosporine to avoid phosphorylation of the GST-fused peptides by the kinases in 
Cos7 cell extracts. Peptide-bound βTrCP1 was detected by immunoblotting. As 
expected, the βTrCP1 bound to the phospho-mimetic peptides, but not the 
unphosphorylated one (Fig. 7A). βTrCP1 bound strongly to GST-10D, and less strongly 
to 8D2S and 8S2D. No βTrCP1 binding was detected for the GST-10S peptide. These 
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results strongly suggest that the phosphorylation of Ser residues is required in the 
βTrCP-binding peptide consisting of 82ESS to 101SPSP. 
Next, we examined the stability of the Cdc25B10D mutant in HeLa cells. Cdc25B 
of wild type, 10D, 10A (all Ser residues in 82ESS to 101SPSP were replaced by 
non-phosphorylatable Ala), and D94A were transfected to HeLa cells and their 
expression was detected in the absence of stress. As indicated in Fig. 7B, the expression 
of the phospho-mimetic Cdc25B10D mutant was less than that of the wild type, 
indicating that Cdc25B10D is unstable, even under unstressed conditions, supporting the 
idea that full βTrCP binding requires phosphorylation. 
Finally, we investigated the contribution of the DAG and DDG βTrCP-binding 
sites to Cdc25B stability in stressed and unstressed conditions. FLAG-Cdc25B of wild 
type, D94A, DAA, or D94A/DAA was transfected to HeLa cells and its expression was 
determined by immunoblotting. Typical expression of such mutants under anisomycin 
stress is shown in Fig. 8A. βTrCP1 binding to the Cdc25B mutant in the presence of 
JNK activity is also shown in Fig. S7. As expected, Cdc25BWT and Cdc25BDAA were 
susceptible to anisomycin treatment and Cdc25BD94A was more refractory to it. The 
degradation of Cdc25BD94A/DAA was quite stable under anisomycin stress. These results 
indicate that the newly identified DAG βTrCP-binding sequence is responsible for 
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stress-induced Cdc25B degradation. We also investigated the stability of such Cdc25B 
proteins in the presence of cycloheximide to estimate their steady-state stability (Fig. 
8B). Cdc25BDAA was more stable than Cdc25BWT, but Cdc25BD94A was even more 
stable than Cdc25BWT or Cdc25BDAA. Here again, the degradation of Cdc25BD94A/DAA 
was not observed with cycloheximide. These results suggest that the newly identified 
Cdc25B N-terminal βTrCP-binding region controls Cdc25B stability under both 
stressful and steady-state conditions and that the N-terminal DAG and constitutive DDG 
βTrCP binding sites cooperatively control Cdc25B stability. 
 
Discussion 
Previously, we showed that the cellular stresses that activate JNK or p38 induce 
Cdc25B degradation and that S101 and S103 are involved in Cdc25B stability (Uchida 
et al., 2009). We also suggested the involvement of the ubiquitin–proteasome system in 
stress-induced Cdc25B degradation. In this report, we identified SCFβTrCP as the 
ubiquitin ligase responsible for non-genotoxic stress-induced Cdc25B degradation. 
Moreover, S101 and S103 are highly phosphorylated by such stresses and are involved 
in ubiquitylation by SCFβTrCP. 
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Our results indicate that non-canonical 94DAG and 101SPSP in Cdc25B play 
important roles in Cdc25B for βTrCP binding. Moreover, an upstream PEST-like 
sequence starting from 82ESS turned out to have a critical role in βTrCP binding to 
Cdc25B. Human Cdc25B has a longer PEST-like sequence than Cdc25A. The entire 
12-amino-acid PEST-like sequence was essential for proper ubiquitylation. These 
results strongly indicate that the PEST-like sequence and SPSP cooperate with DAG for 
Cdc25B ubiquitylation under conditions that activate p38 and JNK. Moreover, the 
newly identified βTrCP-binding sequence around DAG is likely involved in steady-state 
Cdc25B degradation in collaboration with DDG under both stress-induced and 
steady-state conditions, given that the Cdc25BD94A/DAA double mutant was stable 
irrespective of cellular stress and SCFβTrCP barely ubiquitylated Cdc25BD94A/DAA. Hence, 
we safely conclude that Cdc25B stability is regulated mainly by SCFβTrCP-mediated 
ubiquitylation via two independent sites: DAG and DAA. 
The Ser residues in 101SPSP, located downstream from 94DAG, are highly 
phosphorylated upon JNK and p38 activation. In addition, a GST-fused 
phospho-mimetic peptide of 82ESS to 101SPSP bound βTrCP1, whereas that with the 
wild-type PEST-like sequence with SPSP did not, suggesting that the highly 
phosphorylated PEST-like sequence in Cdc25B is critical for βTrCP binding. These 
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results strongly suggest that full phosphorylation of the stretch from 82ESS to 101SPSP is 
required for Cdc25B to bind βTrCP. Such phosphorylation may confer a negative 
charge. The importance of phosphorylation in the upstream sequences to the core DSG 
sequence has also been reported in Cdc25A and REST (Jin et al., 2003; Westbrook et 
al., 2008). It was also reported that the stability of Xenopus Cdc25A is strongly affected 
by negatively charged amino acids surrounding the constitutive βTrCP-binding motif 
DDG (Kanemori et al., 2005). Hence, the βTrCP-binding motif-like DAG sequence in 
Cdc25B functions in βTrCP binding by virtue of the strong negative charge resulting 
from acidic residues, which may enable a strong interaction with βTrCP. Analysis of the 
crystal structure should confirm this. 
Under non-genotoxic stress, the Ser residues of the SPSP sequence are 
preferentially phosphorylated by p38 and JNK. Interestingly, S101 was weakly but 
constitutively phosphorylated under steady-state conditions when both p38 and JNK 
were inactive. These results indicate that an unidentified proline-directed kinase(s) 
phosphorylates S101 in the steady-state condition, which may contribute to Cdc25B 
degradation during the interphase. In this context, Isoda et al. (2009) reported the 
inhibition of phosphorylation by the CDK inhibitor p21 in the corresponding Ser 
residue in Xenopus Cdc25A. Perhaps the interphase-specific CDK-cyclins that are 
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active from the G1 phase through the S phase, such as Cdk2-cyclin E, Cdk2-cyclin A, 
and possibly Cdk4-cyclin D, phosphorylate S101 to keep Cdc25B expression low. The 
identification of a kinase that phosphorylates Cdc25B S101 under steady-state 
conditions is likely important for understanding the post-translational regulation of 
Cdc25B. A need for phosphorylation in the Cdc25B PEST-like sequence for βTrCP 
binding was also suggested. Given that the phosphorylation of Ser residues in the 
PEST-like sequence is a prerequisite for βTrCP binding, it is also important to identify 
the kinase(s) responsible for a full understanding of Cdc25B regulation. More work is 
needed to understand the regulation of Cdc25B stability by phosphorylation under 
steady-state and stress-induced conditions. 
In conclusion, we identified a new site in Cdc25B for non-genotoxic 
stress-induced βTrCP binding and proved that SCFβTrCP is the responsible ubiquitin 
ligase. The newly identified site is DAG, which is thought to be inactive in βTrCP 
binding; it is surrounded by an upstream PEST-like sequence and a downstream SPSP. 
Our results suggest that the full phosphorylation of the PEST-like sequence and SPSP 
are required for βTrCP binding and that the new site and the previously reported DDG 
constitutive βTrCP binding site collaboratively regulate the stability of Cdc25B under 
both stress-induced and steady-state conditions. Cdc25B and Cdc25A are 
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over-expressed in many tumours, and their overexpression is correlated with a poor 
prognosis (Kristjansdottir and Rudolph, 2004; Boutros et al., 2007). The uncontrolled 
expression of Cdc25B is itself toxic, as it induces premature entry into the M phase 
(Karlsson et al., 1999) and possibly genomic instability. Further studies that elucidate 
the regulation of Cdc25B stability should increase our understanding of the role of 
Cdc25B in cell cycle control and the contribution of the deregulation of Cdc25B 
stability to tumorigenesis. 
 
Materials and Methods 
Reagents and plasmids 
Reagents of the highest grade were obtained from Wako (Osaka, Japan) or Sigma. The 
following siRNAs were purchased from Dharmacon: βTrCP1/βTrCP2 (denoted as 
pan-βTrCP siRNA in this report: Margottin-Goguet et al., 2003; Guardavaccaro et al., 
2003), βTrCP1 (5'-UGACAACACUAUCAGAUUA-3'), and βTrCP2 
(5'-GGACUUUAUUACCGCUUUA-3'). The validated stealth RNAi for JNK1 
(5'-GGGCCUACAGAGAGCTAGUUCUUAU-3') and JNK2 
(5'-GCCCAAGGGAUUGUUUGUGCUGCAU-3' and 
5'-GCCAACUGUGAGGAAUUAUGUCGAA-3') were obtained from Invitrogen. The 
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siRNA for luciferase (5'-CGUACGCGGAAUACUUCGA-3') was obtained from 
QIAGEN. Anisomycin, SB202190, PD169316, and SP600125 were obtained from 
Calbiochem. The following cDNAs were used: human Cdc25B1, human Cdc25B3, 
mouse Cdc25B1, mouse p38α, mouse MKK6, mouse JNK1, mouse MKK7, human 
βTrCP1, human βTrCP2, human Skp1, human Skp2, human Cdc4, human Cul1, and 
mouse Rbx1. FLAG, HA, and Myc-tagged expression plasmids were constructed using 
the pEF6/Myc-His vector, which includes the EF1α promoter (Invitrogen), as described 
elsewhere (Uchida et al., 2004). The mutant versions of the above cDNAs were 
generated by PCR-based mutagenesis, and their nucleotide sequences were confirmed 
by sequencing. 
 
Antibodies and proteins 
Active JNK1 kinase was purchased from Invitrogen. The rabbit antibody specific for 
Cdc25B phospho-S101 was obtained from GenScript Corporation (USA) using 
NH2-MD(PO4-)SPSPMDPHMAEC-COOH as the antigen. The rabbit antibodies 
specific for phospho-S103 and phospho-S101/103 were obtained from IBL (Japan) 
using NH2-MDSP(PO4-)SPMDPHMAEC-COOH and 
NH2-MD(PO4-)SP(PO4-)SPMDPHMAEC-COOH as the respective antigens. Each 
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anti-phospho-antibody was affinity purified with antigen peptide before use. The 
antibodies purchased were as follows: mouse anti-TrCP1 was purchased from Zymed; 
Cdc25A (F-6), Cdc25B (C-20), and JNK1 (C-17) antibodies were from Santa Cruz 
Biotechnology; and anti-actin, Myc-tag (9B11), HA-tag 262K, 
phospho-JNK-T183/Y185 (G9), MK2, c-Jun, and phospho-c-Jun-S63II were obtained 
from Cell Signaling. The anti-Cdc25B (AF1649) was obtained from R & D Systems. 
Secondary antibodies labelled with horseradish peroxidase were purchased from DAKO. 
Anti-FLAG-M2-agarose beads were purchased from Sigma. The rabbit anti-FLAG 
serum was raised in house. E. coli-produced GST-fused Cdc25B peptides encompassing 
82ESS to 101SPSP and the phospho-mimetic mutant versions were purified from 
IPTG-induced BL21 cells with glutathione beads (GE Healthcare). 
 
Cells, cell culture, and siRNA or plasmid transfection 
HeLa and Cos7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
containing high glucose (Sigma) supplemented with 10% foetal bovine serum (FBS; 
Hyclone) and antibiotics. HeLa-W40 cells that constitutively expressed FLAG-tagged 
wild-type Cdc25B under the EF1α promoter were also cultured under the same 
conditions (Uchida et al., 2009). We also isolated HeLa cells constitutively expressing 
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the FLAG-tagged Cdc25BDAA mutant (HeLa-DAA34 cells). In these cells, the 
expression of external Cdc25B was roughly 20 to 40-fold higher than that of 
endogenous Cdc25B. Plasmids were transiently transfected with Lipofectamine 2000 
(Invitrogen). The amount of plasmid DNA used for transfection was about 500 ng for a 
6-well plate. HeLa and Cos7 cells were used for assays of stability (degradation) and for 
protein-protein interaction, respectively. The siRNA was transfected using 
Lipofectamine RNAiMAX (Invitrogen). 
 
Biochemical methods and in vitro ubiquitylation assay 
Crude extraction for protein analysis followed by immunoblotting or 
immunoprecipitation was performed as described previously (Uchida et al., 2004). The 
in vitro ubiquitylation assay was performed essentially as described previously 
(Watanabe et al., 2004). Briefly, HA-tagged Rbx1, Skp2, and Cul1, and c-Myc-tagged 
F-box proteins were co-expressed in Cos7 cells, and the SCF complex was recovered by 
immunoprecipitation with anti-c-Myc-agarose (MBL, Japan). 35S-methionine-labelled 
Cdc25B was prepared with a TNT-coupled transcription and translation system 
(Promega). The reaction mixture in a total volume of 20 µL contained SCF complex on 
beads, 35S-labelled Cdc25B (2 µL), 20 µg bovine ubiquitin (Sigma), 0.8 µg human 
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recombinant E1 enzyme (BIOMOL), 1 µg human 6xHis-Ubc5 (Wako, Osaka, Japan), 
and an ATP-regenerating system (2 mM ATP, 10 mM creatine phosphate, 0.35 U/ml 
creatine kinase, 0.6 U/mL inorganic pyrophosphatase), supplemented with 5 µM 
MG132, 0.5 µM okadaic acid, and 1 µM ubiquitin-aldehyde (Boston Biochem). When 
necessary, recombinant active JNK1 (25 ng) was added to the reaction. The mixtures 
were incubated at 37°C for 2 h, followed by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) in a 2–15% gradient gel, and the ubiquitylated 
Cdc25B was visualised using the FUJI BAS system. 
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Figure 1. βTrCP binds Cdc25B. (A) The aligned amino acid sequences of human and 
mouse Cdc25B corresponding to that of human Cdc25A required for βTrCP binding. 
Asterisks indicate amino acids common to all three peptides. (B) Each FLAG-tagged 
cDNA of human Cdc25B1 and B3 and mouse Cdc25B1 was cotransfected with either 
JNK1 and its activator MKK7 or p38α and its activator MKK6, followed by 
immunoblotting to detect the expression of the indicated proteins (JNK1 or p38α was 
cotransfected with its respective activator, MKK7 or MKK6, unless stated otherwise 
and the coexpression of JNK1 and MKK7 or p38α with MKK6 is shown as JNK1 or 
p38, respectively, thereafter). The expression of human Cdc25B1 with a mutation at 
D94 to A of DAG (D94A) was also determined. (C) Either a FLAG-Cdc25BWT or 
Cdc25BDAA with mutations in the constitutive βTrCP-binding sequence DDG was 
cotransfected with Myc-βTrCP1 in the presence or absence of JNK1. Then, 24 h later, 
either Cdc25B binding to βTrCP1 or recovered Cdc25B was determined by 
immunoprecipitation with anti-FLAG beads, followed by immunoblotting with 
anti-Myc or anti-FLAG antibodies (Cdc25B-IP panel). The expression of the indicated 
proteins is also shown (WCE panel). (D) The βTrCP1 binding to Cdc25B fragments of 
the N-terminal 175 amino acids (1–175, 25B–N) or C-terminal fragment (180–580, 
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25B–C), both of which contain an N-terminal FLAG-tag and C-terminal GFP-tag, was 
examined as described in (C). FLAG-GFP was used as a control (Cdc25B-IP panel). 
The expression of the indicated proteins is shown (WCE panel). (E) FLAG-Cdc25BDAA 
and Myc-tagged F-box proteins were cotransfected and their interaction was determined 
by immunoprecipitation and immunoblotting. The interaction between Cdc25BDDA and 
βTrCP1ΔF lacking an F-box sequence (17) was also determined (Cdc25B-IP panel). The 
expression of the indicated proteins is also shown (WCE panel). 
 
Figure 2. Cdc25B is ubiquitylated by SCFβTrCP in vitro. (A) 35S-methionine-labelled 
Cdc25BDAA was incubated with each SCF complex in the presence or absence of JNK1, 
and ubiquitylation was determined as described in the Materials and Methods. (B) 
35S-methionine-labelled Cdc25BDAA was incubated with each SCFβTrCP1 or SCFΔβTrCP1 
complex in the presence or absence of JNK1, and ubiquitylation was determined as 
described in (A). (C) SCFβTrCP1-mediated ubiquitylation of 35S-methionine-labelled 
Cdc25BWT (wild type) or Cdc25BDAA was determined as described in (A). (D) 
35S-methionine-labelled Cdc25BDAA of S101/103 (wild type), or with a mutation of 
S101A, S103A, or S101/103A, was incubated with SCFβTrCP1 to determine 
ubiquitylation as described in (A). 
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Figure 3. βTrCP1/2 depletion stabilises Cdc25B. (A) HeLa cells were depleted of 
both βTrCP1 and 2 with siRNA (either pan-βTrCP or combined siRNA for βTrCP1 and 
2). Luci indicates siRNA against luciferase used as a control. After 24 h, HeLa cells 
were treated with 50 ng/ml anisomycin for 30 min. The expression of endogenous 
Cdc25B was determined by immunoprecipitation followed by immunoblotting. The 
expression of the indicated proteins was determined by immunoblotting. (B) HeLa-W40 
cells transfected with either siRNA for Luci or pan-βTrCP were treated with 
cycloheximide (CHX, 50 µg/mL), and expression of the indicated proteins was 
determined by immunoblotting at the indicated times. The relative Cdc25B expression 
is shown in the lower panel with the value at time 0 set at 100. The bars indicate the 
standard deviation (SD) of three independent experiments. (C) The expression of 
Cdc25BDAA in HeLa-DAA34 cells in the presence of CHX was determined as described 
in (B). (D) HeLa-W40 cells transfected with either siRNA for Luci or pan-βTrCP were 
treated with 50 ng/mL anisomycin, and the expression of the indicated proteins was 
determined as described in (B). 
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Figure 4. Cdc25B S101 and S103 are phosphorylated by non-genotoxic insults. 
(A) HeLa-W40 cells that expressed FLAG-Cdc25B were treated with 50 ng/mL 
anisomycin. At the indicated times, Cdc25B was immunoprecipitated, and 
phosphorylation was detected with antibodies. The expression of FLAG-Cdc25B, c-Jun, 
MK2, and β-actin are also shown. (B) HeLa-W40 cells were treated with 300 mM NaCl, 
and phosphorylation at S101 and S103 and the expression of the indicated proteins was 
detected, as described in (A). (C) HeLa-W40 cells were treated with each inhibitor (5 
µM each of SB202190 and PD169316 for p38 and 20 µM SP600125 for JNK, or a 
combination of SB and SP or PD and SP to inhibit p38 and JNK) 1 h before the 50 
ng/mL anisomycin challenge. Cell extracts were prepared at 10 min, followed by the 
immunoprecipitation of Cdc25B. Phosphorylation at S101 and S103 and the expression 
of the indicated proteins were determined by immunoblotting. (D) HeLa-W40 cells 
were treated with siRNA for Luc or JNK (the siRNA for JNK was a mixture of one 
siJNK1 and two siJNK2). After 24 h, the cells were treated with 50 ng/mL anisomycin 
for 10 min and cell extracts were prepared. The phosphorylation of Cdc25B at S101 and 
S103 and the expression of the indicated proteins were determined by immunoblotting. 
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Figure 5. Cdc25B peptide from 94DAG to 101SPSP is essential, but not sufficient, for 
Cdc25B ubiquitylation by SCFβTrCP. (A) FLAG-Cdc25B of the wild type or indicated 
mutants was cotransfected with Myc-βTrCP1 in the presence or absence of JNK1. Then, 
24 h later, Cdc25B-bound βTrCP1 was detected by the immunoprecipitation of Cdc25B, 
followed by immunoblotting (Cdc25B-IP panel). The expression of the indicated 
proteins is also shown (WCE panel). (B) In vitro ubiquitylation by SCFβTrCP1 of 
Cdc25BDAA with wild-type DAG, or G96A or S101/103A mutations was determined, as 
described in Fig. 2A. (C) Phosphorylated or unphosphorylated Cdc25B peptides based 
on DAGLCMDSPSP that was conjugated with agarose beads was incubated with 
Myc-βTrCP1-expressing Cos7 cell extracts and the βTrCP1 bound to peptides was 
detected by immunoblotting. 
 
Figure 6. The PEST-like sequence is required for efficient ubiquitylation of 
Cdc25B. (A) The following FLAG-Cdc25BDAA-based mutants were cotransfected with 
Myc-βTrCP1 in the presence or absence of JNK1: WT with an intact PEST-like 
sequence; 8SA (-PEST) with mutations of eight serine residues in the PEST-like 
sequence to alanine; S101/103A; or D94A. After 24 h, Cdc25B was 
immunoprecipitated, and Cdc25B-bound βTrCP1 was detected by immunoblotting 
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(Cdc25B-IP panel). The expression of the indicated proteins was also determined (WCE 
panel). (B) FLAG-Cdc25BDAA with an intact PEST-like sequence (WT) or with SS to 
AA mutations of two serine residues in three ESS units or one LSS unit was 
cotransfected with Myc-βTrCP1 in the presence or absence of JNK. The Cdc25B-bound 
βTrCP1 and protein expression are shown as indicated in (A). Cdc25BD94A was used as 
a negative control. (C) The 35S-labelled Cdc25BDAA-based proteins used in (B) were 
processed to detect in vitro ubiquitylation, as described in Fig. 2A. 
 
Figure 7. A peptide encompassing 82ESS to 101SPSP is a possible βTrCP-binding 
sequence in Cdc25B. (A) GST-fused Cdc25B-derived peptides consisting of 82ESS to 
101SPSP were mixed with crude cell extracts prepared from Myc-tagged 
βTrCP1-transfected Cos7 cells, and this was followed by the recovery of proteins bound 
to GST-fused peptides. The recovered βTrCP1 was detected with anti-Myc antibody. 
The reaction mixture included 1 µM staurosporine to avoid the phosphorylation of Ser 
residues in the peptides by kinases present in the cell extracts. (B) FLAG-Cdc25B of 
wild type, 10D (all Ser residues in 82ESS to 101SPSP were replaced with Asp), 10A (all 
Ser residues in 82ESS to 101SPSP were replaced with Ala), or D94A was transfected to 
HeLa cells and their expression was determined by immunoblotting. 
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Figure 8. DAG and DDG collaboratively regulate Cdc25B stability. FLAG-tagged 
Cdc25BWT, Cdc25BD94A, Cdc25BDAA, or Cdc25BD94A/DAA was transfected to HeLa cells, 
which were treated with 100 ng/mL anisomycin (panel A) or 50 µg/mL cycloheximide 
(panel B) 24 h after transfection. Crude cell extracts were prepared at the indicated 
times and the expression of Cdc25B, c-Jun, and β-actin was determined by 
immunoblotting. The relative Cdc25B expression is also shown with the value at time 0 
set to 100. The bars indicated the SD of five independent experiments. In (A) and (B), 
the relative densitometric values of the expression of Cdc25BWT, Cdc25BD94A, 
Cdc25BDAA, and Cdc25BD94A/DAA were 1, 1.98 ± 0.79, 1.77 ± 0.59, and 4.21 ± 1.2, 
respectively. 
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Supplementary Figure legends 
Fig. S1. SCFβTrCP ubiquitylates Cdc25B. (A) 35S-methione-labelled Cdc25BDAA of 
human B1, human B3, and mouse B1 was incubated with the SCFβTrCP complex in the 
presence or absence of JNK1, and the ubiquitylation was determined as described in the 
Materials and Methods. The ubiquitylation of 35S-methione-labelled Cdc25B1DAA with 
additional mutations of D94A or S101/103A was also determined. (B) The following 
FLAG-Cdc25BDAA-based mutants were cotransfected with Myc-βTrCP1 in the presence 
or absence of JNK1: WT without other mutation; S101A; S103A; S101/103A; or D94A. 
Then, 24 h later, Cdc25B-bound βTrCP1 was detected by the immunoprecipitation of 
Cdc25B, followed by immunoblotting (Cdc25B-IP panel). The expression of the 
indicated proteins is also shown (WCE panel). 
 
Fig. S2. The depletion of βTrCP1/2 with siRNA stabilises Cdc25B. (A) HeLa cells 
constitutively expressing FLAG-Cdc25B (HeLa-W40 cells) were transfected with 
control siRNA (against luciferase (Luci)) or siRNA that targets both βTrCP1 and 
βTrCP2 (βTrCP). After 24 h, the expression of FLAG-Cdc25B, endogenous Cdc25A, 
βTrCP1, and β-actin was determined by immunoblotting. (B) HeLa cells were 
transfected with siRNA against luciferase (Luci) or βTrCP (pan-βTrCP or βTrCP1 + 2). 
After 24 h, these cells were further transfected with FLAG-Cdc25BDAA with or without 
JNK1 and MKK7. After 24 h, the expression of Cdc25BDAA and the indicated proteins 
was determined by immunoblotting. (C) HeLa-DAA34 cells expressing 
FLAG-Cdc25BDAA were transfected with siRNA against either Luci or pan-βTrCP and 
challenged with 50 ng/mL anisomycin. The expression of the indicated proteins was 
determined by immunoblotting at the indicated time points. Quantitative results for the 
expression of Cdc25BDAA are shown. The results shown are the average of three 
independent experiments with the SD. 
 
Fig. S3. Cdc25B S101 and S103 are phosphorylated by JNK or by UV irradiation. 
(A) The specificity of phospho-specific antibodies was evaluated using in vitro 
phosphorylated Cdc25B. The GST-fused Cdc25B N-terminal fragment (1–175) purified 
from E. coli was phosphorylated by JNK1 and probed with the indicated antibodies. 
(B) HeLa-W40 cells were irradiated with UV at 20 J/m2, and cell extracts were prepared 
at the indicated times. After the immunoprecipitation of Cdc25B with anti-FLAG beads, 
the phosphorylation status of the indicated amino acids was determined by 
immunoblotting with each phospho-specific antibody. The expression of the indicated 
proteins is also shown. 
 Fig. S4. p38 and JNK are involved in phosphorylation at S101 and S103. 
HeLa-W40 cells were treated with the p38 inhibitor SB202190 (A), p38 inhibitor 
PD169316 (B), or JNK inhibitor SP600125 (C) at the indicated concentration 1 h before 
the challenge with 50 ng/mL anisomycin. FLAG-Cdc25B was recovered with 
anti-FLAG agarose beads, and then the expression and phosphorylation of S101 or S103 
was determined by immunoblotting with specific antibodies. The expression of other 
proteins was also determined. (D) HeLa cells were transfected with the wild-type or 
kinase-dead form of JNK1 with MKK7. After 24 h, the expression of endogenous 
Cdc25B was determined by immunoprecipitation followed by immunoblotting. The 
expression of the indicated proteins is also shown. The transfection efficiency of JNK1 
was about 75% (range 70–80%). 
 
Fig. S5. Cdc25B DAG mutations stabilise Cdc25B. (A) FLAG-Cdc25B of the wild 
type or D94A, G96A, or S101/103A mutants was cotransfected with or without JNK1. 
The expression of the indicated proteins was determined 24 h after transfection by 
immunoblotting. (B) Cdc25B of the wild type, D94A, or S101/103A was cotransfected 
with or without JNK1. After 24 h, cell extracts were prepared, and Cdc25B was 
immunoprecipitated with anti-FLAG beads, followed by the determination of Cdc25B 
S101/103 phosphorylation by immunoblotting. 
 
Fig. S6. The Cdc25B PEST-like sequence plays an important role in JNK-induced 
degradation. (A) FLAG-Cdc25B of the wild-type or PEST-like sequence mutant (all 
eight serine residues in the PEST-like sequence were mutated to alanine, 8SA [-PEST]), 
S101/103A, or D94A mutants were transfected into HeLa cells in the presence or 
absence of JNK1. The expression of the indicated proteins was determined 24 h after 
transfection. (B) FLAG-Cdc25B of the wild-type or PEST-like sequence mutants in 
which different numbers of serine residues were mutated to alanine were transfected to 
HeLa cells with or without JNK1. The expression of the indicated proteins was 
determined 24 h after transfection. (C) FLAG-Cdc25B mutants with mutations in two 
serine residues in each ESS unit or in LSS in the PEST-like sequence were transfected 
with or without JNK1. The expression of the indicated proteins was determined 24 h 
after transfection. (D) FLAG-Cdc25B of wild type or the E88A, E91A, or D94A mutant 
was transfected with or without JNK1. The expression of the indicated proteins was 
determined 24 h after transfection. (E) Cdc25B of the wild type, 8SA (-PEST), 
S101/103A, or D94A was cotransfected with or without JNK1. After 24 h, cell extracts 
were prepared, and Cdc25B was immunoprecipitated with anti-FLAG beads, followed 
by the determination of Cdc25B S101/103 phosphorylation by immunoblotting. 
 
Fig. S7. DAG is a JNK-dependent βTrCP1 site in Cdc25B and DDG is a 
JNK-independent site. FLAG-Cdc25B of the wild type or D94A, DAA, or 
D94A/DAA mutants was transfected with or without JNK1. After 24 h, the 
FLAG-Cdc25B proteins were recovered by immunoprecipitation and the βTrCP1 bound 
to FLAG-Cdc25B or recovered FLAG-Cdc25B was determined by immunoblotting 































































































































Time after UV irradiation
0 15 30 (min)

























0 5 10 20 0
- + + + + - + + + +






















































































































WT E88A E91A D94A






































- + - + - + - + - + - + - + - +
WT D9
4A
DA
A
D9
4A
,DA
A
Fig. S7
βTrCP1
Cdc25B
JNK1
βTrCP1
Cdc25B
MKK7
JNK1
β-actin
Cdc25B-IP WCE
